AVE 0.00% 0.2¢ avecho biotechnology limited

eureka report, page-13

  1. 5,322 Posts.
    GC Ive read Novartis Voltaren sales globally tick around US$800 Mill pa. So Brendan's fig of $5-6 Mill revenue to POH in license fees would be too high for just India and way too low for a Novartis TPM Voltaren Global roll out. No matter- there is significant money to flow from Diclo for POH. It will all become clear over coming months
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.